含克力芝方案在HIV感染妊娠妇女ART的疗效和安全性

发布时间：2018-03-28 16:35

  本文选题：艾滋病　切入点：妊娠妇女　出处：《中国艾滋病性病》2017年09期

【摘要】：目的探讨克力芝在艾滋病病毒(HIV)感染妊娠妇女中抗病毒治疗(ART)的效果和安全性。方法采集2011年1月至2016年6月,在北京佑安医院性病艾滋病门诊,接受基于克力芝的三联抗病毒治疗的HIV感染妊娠妇女的临床资料,分析ART的疗效与安全性。结果 210例HIV感染孕妇基线时CD4~+T淋巴细胞(简称CD4细胞)计数为(365±171)个/μL,治疗24周时CD4细胞计数为(522±198)个/μL,治疗48周时CD4细胞计数为(546±203)个/μL,与基线相比差异有统计学意义(P均0.05);病毒载量检测不到者所占的比例在基线、24周和48周时分别为12.4%、91.0%和96.7%,与基线相比差异有统计学意义(P均0.05);胃肠道反应、贫血和血脂异常发生率分别为16.2%、12.4%和7.6%,无严重不良反应发生。结论基于克力芝的三联抗病毒治疗对于HIV感染孕妇疗效显著,安全性良好,可在HIV感染妊娠妇女中进一步推广。
[Abstract]:Objective to investigate the efficacy and safety of anti-viral therapy (ART) in pregnant women infected with HIV / AIDS (HIV / AIDS). Methods from January 2011 to June 2016, Cleidge was collected from the STD / AIDS clinic of Beijing Youan Hospital. Clinical data of pregnant women with HIV infection who received triple antiviral therapy based on Clariz, Results the counts of CD4 ~ T lymphocytes (CD4 cells) in 210 pregnant women with HIV infection were 365 卤171 / 渭 L at baseline, 522 卤198 / 渭 L on 24 weeks after treatment, and 546 卤203 on 48 weeks after treatment. / 渭 L, the difference was statistically significant (P < 0.05) compared with baseline, the proportion of patients whose viral load could not be detected was 12.41.0% and 96.7% at 24 and 48 weeks of baseline, respectively, and the difference was statistically significant compared with baseline (P < 0.05), gastrointestinal reaction, Gastrointestinal reaction, Gastrointestinal reaction, Gastrointestinal reaction, Gastrointestinal reaction, Gastrointestinal reaction, Gastrointestinal reaction, Gastrointestinal reaction, Gastrointestinal reaction, Gastrointestinal reaction, The incidence of anemia and dyslipidemia were 12.4% and 7.6%, respectively. There was no serious adverse reaction. Conclusion the triple antiviral therapy based on Claridum is effective and safe for pregnant women with HIV infection, and can be further popularized in pregnant women infected with HIV.
【作者单位】： 首都医科大学附属北京佑安医院感染中心;
【分类号】：R714.251
，

本文编号：1677142